PUNE, India, March 10, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Obesity - Pipeline Review, H2 2015" market research report providing an overview of the therapeutic pipeline for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.
Complete report on Obesity H2 2015 pipeline review with 169 market data tables and 17 figures, spread across 560 pages is available at http://www.rnrmarketresearch.com/obesity-pipeline-review-h2-2015-market-report.html
Obesity pipeline of 99 companies discussed in this research for H2 2015 include that by Abeome Corporation, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, Akron Molecules AG, Alize Pharma SAS, Amabiotics SAS, Ambrx, Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Asubio Pharma Co., Ltd., AtheroNova Inc., Avaxia Biologics, Inc., BioLingus AG, BioRestorative Therapies, Inc., BioTime, Inc., Boehringer Ingelheim GmbH, Braasch Biotech LLC, Bristol-Myers Squibb Company, Camurus AB, Carmot Therapeutics, Inc., Chronos Therapeutics Limited, CohBar, Inc., CoMentis, Inc., Daiichi Sankyo Company, Limited, Deltanoid Pharmaceuticals Inc., Diabetica Limited, DiscoveryBiomed, Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperion Therapeutics, Inc., Euroscreen S.A., F. Hoffmann-La Roche Ltd., FibroGen, Inc., Galenea Corp., Genfit SA, GlaxoSmithKline Plc, GTx, Inc., Gubra ApS, Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Helsinn Healthcare S.A., Hyundai Pharmaceutical Co., Ltd., Insusense Therapeutics ApS, Ionis Pharmaceuticals, Inc., Jenrin Discovery, Inc., Johnson & Johnson, Kainos Medicine, Inc., Kissei Pharmaceutical Co., Ltd., Lead Discovery Center GmbH, LEO Pharma A/S, LG Life Science LTD., M Pharmaceutical Inc., Magnus Life Science, MAKScientific, LLC, MedImmune, LLC, Mitsubishi Tanabe Pharma Corporation, Molecular Design International, Inc., NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, nLife Therapeutics, S.L., Nordic Bioscience A/S, Novo Nordisk A/S, ObeTherapy Biotechnology, Omeros Corporation, OPKO Health, Inc., Orbis Biosciences, Inc., Orchid Chemicals & Pharmaceuticals Ltd, Orexigen Therapeutics, Inc., Pfizer Inc., PharmaIN Corporation, PolyNovo Limited, Prometheon Pharma, LLC, Radius Health, Inc., Regulus Therapeutics Inc., Reviva Pharmaceuticals Inc., Rhythm Pharmaceuticals, Inc., Saniona AB, Sanofi, Shanghai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sinil Pharmaceutical Co., Ltd, Sirona Biochem Corp, Sorrento Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Suven Life Sciences Ltd., Takeda Pharmaceutical Company Limited, Toray Industries, Inc., Umecrine AB, Vicore Pharma AB, Viking Therapeutics, Inc., Virocan Therapeutics Private Limited, WhanIn Pharmaceutical Co., Ltd., Xenetic Biosciences plc, XL-protein GmbH, Zafgen Inc., Zealand Pharma A/S and Zydus Cadila Healthcare Limited.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Order a copy of Obesity Pipeline Review H2 2015 report at http://www.rnrmarketresearch.com/contacts/purchase?rname=466308
Another research on Obesity titled Abdominal Obesity - Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Abdominal Obesity. It covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This research also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Abdominal Obesity. It assesses the Abdominal Obesity therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. Please note: This report requires certain updates. All the information is available but it requires 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Read more at http://www.rnrmarketresearch.com/abdominal-obesity-pipeline-insights-2016-market-report.html
Explore more reports on obesity drugs market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/obesity-drugs
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Connect with Us:
G+/Google Plus: https://plus.google.com/104156468549256253075/posts
SOURCE RnR Market Research